Enzalutamide (Xtandi) for non-metastatic prostate cancer

featured image
Indications: Prostate cancer
Therapeutic Areas: Male Reproductive Cancer
Year: 2017

Enzalutamide (Xtandi) is a drug which blocks the effect of the hormone testosterone on the prostate and so slows down the growth of the cancer. Enzalutamide is taken as four capsules once a day. If licenced in the UK, it could provide an additional treatment option for patients with non-metastatic prostate cancer